- Report
- June 2023
- 338 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- January 2020
- 473 Pages
Global
From €4736EUR$4,899USD£4,068GBP
- Report
- October 2018
- 104 Pages
Global
From €2659EUR$2,750USD£2,284GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£830GBP
Lumigan is a brand name for the drug bimatoprost, an ophthalmic solution used to treat glaucoma and other eye disorders. It is a prostaglandin analog, which works by decreasing the pressure in the eye by increasing the outflow of fluid from the eye. Lumigan is available in both a 0.03% and 0.01% concentration, and is typically administered once daily in the evening. It is available in both a single-use bottle and a multi-use bottle.
Lumigan is a popular treatment for glaucoma and other eye disorders, and is widely prescribed by ophthalmologists. It is also used off-label to treat alopecia, a condition characterized by hair loss. Lumigan is generally well-tolerated, with the most common side effects being eye irritation, redness, and dryness.
The Lumigan market is highly competitive, with a number of companies offering similar products. Some of the major players in the market include Allergan, Pfizer, Novartis, Merck, and Bausch & Lomb. Show Less Read more